• 1
    Al-Sarraf, M., Wong, P., Sardesai, S., and Vaitkevicius, V. K.: Clinical immunologic responsiveness in malignant disease. Cancer 26: 262268, 1970.
  • 2
    Anderson, P. N., Klein, D. L., Bias, W. B., Mullins, G. M., Burke, P. J., and Santos, G. W.: Cell-mediated immunological reactivity of patients and siblings to blasts from acute adult leukemia. Israel J. Med. Sci., in press.
  • 3
    Borel, Y., and Schwartz, R.: Inhibition of immediate and delayed hypersensitivity in the rabbit by 6-mercaptopurine. J. Immunol. 92: 754761, 1964.
  • 4
    Braine, H. G., Burke, P. J., Humphrey, R. L., Kvols, L. K., Mullins, G. M., and Owens, A. H., Jr.: Successful management of infection during induced aplasia in acute leukemia (AML), multiple myeloma (MM), and solid tumors (ST). Proc Assoc. Cancer Res., 15: 185, 1974. (Abstract).
  • 5
    Bruce, W. R., Meeker, B. E., and Valeriote, F. A.: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J. Natl. Cancer Inst. 37: 233245, 1966.
  • 6
    Buckner, C. D., Rudolph, R. H., Fefer, A., Ebstein, R. B., Funk, D. D., Neiman, P. E., Slichter, S. J., Storb, R., and Thomas, E. D.: High-dose cyclophosphamide therapy for malignant disease. Cancer 29: 357365, 1972.
  • 7
    Burkitt, D., Hutt, M. S. R., and Wright, D. H.: The African lymphoma. Preliminary observations on response to therapy. Cancer 18: 399410, 1965.
  • 8
    Defronzo, R. A., Colvin, O. M., Braine, H., Robertson, C. L., and Davis, P. J.: Cyclophosphamide and the kidney. Cancer 33: 483491, 1974.
  • 9
    Friedman, R. M., Buckler, C. E., and Baron, S.: The effect of aminomethylpteroylglutamic acid on the development of skin hypersensitivity and antibody formation in guinea pigs. J. Exp. Med. 114: 173183, 1961.
  • 10
    Gottlieb, J. A., Mendelson, D., and Serpick, A. A.: An evaluation of large intermittent intravenous doses of cyclophosphamide (NSC-26271) in the treatment of metastatic malignant melanoma. Cancer Chemother. Rep. 54: 365367, 1970.
  • 11
    Harris, J. E., and Stewart, T. H. M.: Recovery of mixed lymphocyte reactivity (MLR) following chemotherapy in man. In Proceedings of the Sixth Leucocyte Culture Conference. New York, Academic Press, 1972; pp. 555579.
  • 12
    Hersh, E. M., and Oppenheim, J. J.: Inhibition of in vitro lymphocyte transformation during chemotherapy in man. Cancer Res. 27: 98105, 1967.
  • 13
    Hoyer, J. R., Hoyer, L. W., Good, R. A., and Condie, R. M.: The effect of 6-mercaptopurine on delayed hypersensitivity in guinea pigs. J. Exp. Med. 116: 679685, 1962.
  • 14
    Lamb, D., Pilney, F., Kelly, W. D., and Good, R. A.: A comparative study of the incidence of anergy in patients with carcinoma, leukemia, Hodgkin's disease and other lymphomas. J. Immunol. 89: 555558, 1962.
  • 15
    Landy, M., and Lamb, E.: Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen. Proc. Soc. Exp. Biol. Med. 82: 593598, 1953.
  • 16
    Mendelson, D., Block, J. B., and Serpick, A. A.: Effect of large intermittent intravenous doses of cyclophosphamide in lymphoma. Cancer 25: 715720, 1970.
  • 17
    Mitchell, M. S., and DeConti, R. C.: Immuno-suppression by 5-fluorouracil. Cancer 26: 884889, 1970.
  • 18
    Mullins, G. M., and Colvin, M.: Intensive cyclophosphamide therapy in solid tumors. Cancer Chemother. Rep., in press.
  • 19
    O'Connell, T. X., and Berenbaum, M. C.: Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res. 34: 15861591, 1974.
  • 20
    Santos, G. W., Owens, A. H., Jr., and Sensen-brenner, L. L.: Effects of selected cytotoxic agents on antibody production in man: a preliminary report. Ann. N.Y. Acad. Sci. 114: 404422, 1964.
  • 21
    Santos, G. W., and Owens, A. H., Jr.: 19S and 7S antibody production in the cyclophosphamide- or methotrexate-treated rat. Nature 209: 622624, 1966.
  • 22
    Santos, G. W., Burke, P. J., Sensenbrenner, L. L., and Owens, A. H., Jr.: Rationale for the use of cyclophosphamide as immunosuppression for marrow transplants in man. In International Symposium on Pharmacologic Treatment in Organ and Tissue Transplantation, A.Bertelli and A. P.Monaco, Eds. Amsterdam, Exerpta Medica Foundation, 1970; pp. 2431.
  • 23
    Santos, G. W., Sensenbrenner, L. L., Burke, P. J., Colvin, M., Owens, A. H., Jr., Bias, W. B., and Slavin, R. E.: Marrow transplantation in man following cyclophosphamide. Transplant. Proc. 3: 400404, 1971.
  • 24
    Santos, G. W., Sensenbrenner, L. L., Burke, P. J., Mullins, G. M., Bias, W. B., Tutschka, P. J., and Slavin, R. E.: The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc. 4: 559564, 1972.
  • 25
    Santos, G. W., Mullins, G. M., Bias, W. B., Anderson, P. N., Graziano, K. D., Klein, D. L., and Burke, P. J.: Immunologic studies in acute leukemia, In Conference and Workshop on Cellular Immune Reactions to Human Tumor-Associated Antigens, R. B., Herberman, C. E. Gaylord, Eds. Natl. Cancer Inst. Monogr., 37: 69, 1973.
  • 26
    Santos, G. W.: Immunosuppression for clinical marrow transplantation. Semin. Hematol. 11: 341351, 1974.
  • 27
    Slavin, R. E., Millan, J. C., and Mullins, G. M.: Pathology of high dose intermittent cyclophosphamide therapy. Human Pathol., in press.
  • 28
    Soloway, A. C., and Rapaport, F. T.: Immunologic responses in cancer patients. Surg. Gynecol. Obstet. 121: 756760, 1965.
  • 29
    Storb, R., Buckner, C. D., Dillingham, L. A., and Thomas, E. D.: Cyclophosphamide regimens in Rhesus monkeys with and without marrow infusion. Cancer Res. 30: 21952203, 1970.
  • 30
    Turk, J. L.: Studies on the mechanism of action of methotrexate and cyclophosphamide on contact sensitivity in the guinea pig. Int. Arch. Allergy 24: 191200, 1964.
  • 31
    Winkelstein, A.: Mechanisms of immunosuppression: effects of cyclophosphamide on cellular immunity in the guinea pig. Blood 41: 273284, 1973.